The independent source for health policy research, polling, and news.
30,301 - 30,320 of 112,160 Results
The biggest generic threat to Allergan is to its eye treatment drug Restasis. The company has taken various steps to shield Restasis from competition, notably selling its patents to an Indian tribe in New York state to avoid a U.S. Patent and Trademark Office hearing on the validity of the drug’s patents.
In a novel arrangement, drugmaker Spark Therapeutics will offer discounts based on whether or not the drug, Luxturna, works initially and remains effective.
Today's early morning highlights from the major news organizations.
A selection of opinions on health care from news outlets around the country.
Read recent commentaries about drug-cost issues.
News outlets report on stories related to pharmaceutical pricing.
Media outlets report on news from North Carolina, California, Illinois, Florida, Missouri, Colorado, Ohio and Connecticut.
Next year, people who qualify for Medicaid and have a body mass index of 30 or higher will have access to at least 12 visits a year with a healthcare professional. News outlets also report on Medicaid developments in Colorado, California, Maryland and Illinois.
Under the proposed changes, risk scores used to set payments would take into account certain diagnoses of mental health disorders, substance abuse disorders and chronic kidney disease. Meanwhile, the Department of Health and Human Services has finalized a rule that offers providers and payers more flexibility to share substance abuse patients' data.
Immunotherapy -- using a patient's own immune system to fight cancer -- is sparking a revolution in cancer treatment. But with it comes a whole load of side effects and complications that even doctors can't predict until patients get them. In other public health news: Alzheimer's, hep C, obesity and diabetes, autism and more.
Paleness, sweating and drooping around the eyes can be tell-tale signs if someone is sick. A new study finds that people can pick up on those subtle clues.
The van parks outside Baltimore Central Booking and Intake Center with a sign advertising its services to try to help people right as they're released from jail.
The opioid epidemic has sparked a huge growth in the extremely profitably addiction treatment industry -- but there is little regulation around these centers that are making a lot of money off sick and needy patients. The New York Times offers a deeper look.
Few undocumented residents are able to obtain help for chronic aging issues before their problems become bad enough to send them to the ER, where they are guaranteed emergency care. The financial burden of treating an aging, uninsured population in the coming years will put stress on a system that is already struggling with high costs.
Alex Azar, who has been tapped to replace former Health and Human Services Secretary Tom Price, has been criticized for his close ties to the pharmaceutical industry.
Hospitals and big pharma are waging a war over the 340B program, which requires pharmaceutical companies to give steep discounts to hospitals and clinics that serve high volumes of low-income patients.
News that Senate Finance Committee Chairman Orrin Hatch (R-Utah) will retire after this year sent ripples through the health care industry.
Majority Whip Steve Scalise (R-La.) said that getting rid of the health law and tackling Medicaid regulations would be top priorities for the coming year. Meanwhile, Hillary Clinton has called on Congress to fully re-fund the CHIP program, saying that the lawmakers' short-term solution isn't good enough.
Today's early morning highlights from the major news organizations.
A selection of opinions on health care from news outlets around the country.
© 2026 KFF